These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 1833049)

  • 1. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity.
    Kawase I; Komuta K; Shirasaka T; Hara H; Tanio Y; Watanabe M; Saito S; Ikeda T; Masuno T; Kishimoto S
    Jpn J Cancer Res; 1989 Nov; 80(11):1089-97. PubMed ID: 2514171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells.
    Kawase I; Shirasaka T; Ikeda T; Hara H; Tanio Y; Watanabe M; Saito S; Masuno T; Kishimoto S; Yamamura Y
    Jpn J Cancer Res; 1989 Nov; 80(11):1098-105. PubMed ID: 2481664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).
    Shirasaka T; Kawase I; Okada M; Kitahara M; Ikeda T; Komuta K; Hosoe S; Yokota S; Masuno T; Kishimoto S
    Cancer Immunol Immunother; 1989; 30(4):195-204. PubMed ID: 2598189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acidic polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2.
    Kim KH; Lee YS; Jung IS; Park SY; Chung HY; Lee IR; Yun YS
    Planta Med; 1998 Mar; 64(2):110-5. PubMed ID: 9525101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effector mechanism in concomitant immunity potentiated by intratumoral injection of Nocardia rubra cell wall skeleton.
    Ogura T; Hara H; Yokota S; Hosoe S; Kawase I; Kishimoto S; Yamamura Y
    Cancer Res; 1985 Dec; 45(12 Pt 1):6371-5. PubMed ID: 4063987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction.
    Yokota S; Shirasaka T; Nishikawa H; Hosoe S; Ikeda T; Komuta K; Kawase I; Masuno T; Ogura T; Kishimoto S
    Cancer Immunol Immunother; 1988; 26(1):11-7. PubMed ID: 3257899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
    Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
    Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
    Chao TY; Ohnishi H; Chu TM
    Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.